Ensovibep

恩韦贝普

Report date: 2023/03/28 20:00:38

Base Information

Drug NameEnsovibep
Drug Alias NameMP-0420
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionVirus internalization inhibitorsCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporePoland +[14] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesMolecular Partners Ag
China Registration ClassN/A

Develop Information

Active CompaniesMolecular Partners AgNational Institute Of Allergy And Infectious Diseases (Niaid)
Inactive CompaniesNovartis Pharma Ag
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A